Cabaletta Bio (CABA) Projected to Release Quarterly Earnings on Monday

Cabaletta Bio (NASDAQ:CABA) is projected to announce its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Cabaletta Bio to announce earnings of ($0.33) per share and revenue of $1.67 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Cabaletta Bio (NASDAQ:CABA) last released its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.03. On average, analysts expect Cabaletta Bio to post ($1.34) EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Cabaletta Bio Price Performance

NASDAQ:CABA opened at $1.51 on Monday. The company has a market cap of $256.01 million, a P/E ratio of -0.96 and a beta of 3.56. The firm’s fifty day moving average price is $2.30 and its two-hundred day moving average price is $2.84. Cabaletta Bio has a one year low of $1.32 and a one year high of $4.23.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on CABA shares. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a research report on Tuesday, September 1st. William Blair raised Cabaletta Bio to a “strong-buy” rating in a report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Thursday, October 15th. Wells Fargo & Company cut their price target on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. Finally, Wall Street Zen cut Cabaletta Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 17th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.60.

About Cabaletta Bio

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.